vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Vericel Corp (VCEL). Click either name above to swap in a different company.
FIRSTSUN CAPITAL BANCORP is the larger business by last-quarter revenue ($110.0M vs $92.9M, roughly 1.2× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 19.6%, a 5.4% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.9%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
FSUN vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $92.9M |
| Net Profit | $21.6M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 19.6% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | -8.4% | 17.3% |
| EPS (diluted) | $0.76 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $92.9M | ||
| Q3 25 | $107.3M | $67.5M | ||
| Q2 25 | $105.6M | $63.2M | ||
| Q1 25 | $96.2M | $52.6M | ||
| Q4 24 | $98.7M | $75.4M | ||
| Q3 24 | $98.2M | $57.9M | ||
| Q2 24 | $96.2M | $52.7M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | $23.2M | ||
| Q3 25 | $23.2M | $5.1M | ||
| Q2 25 | $26.4M | $-553.0K | ||
| Q1 25 | $23.6M | $-11.2M | ||
| Q4 24 | $16.4M | $19.8M | ||
| Q3 24 | $22.4M | $-901.0K | ||
| Q2 24 | $24.6M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | 24.1% | ||
| Q3 25 | 26.4% | 5.1% | ||
| Q2 25 | 31.2% | -3.2% | ||
| Q1 25 | 30.9% | -24.3% | ||
| Q4 24 | 20.4% | 24.5% | ||
| Q3 24 | 29.1% | -4.3% | ||
| Q2 24 | 32.3% | -11.5% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | 25.0% | ||
| Q3 25 | 21.6% | 7.5% | ||
| Q2 25 | 25.0% | -0.9% | ||
| Q1 25 | 24.5% | -21.4% | ||
| Q4 24 | 16.6% | 26.3% | ||
| Q3 24 | 22.8% | -1.6% | ||
| Q2 24 | 25.5% | -8.9% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | $0.46 | ||
| Q3 25 | $0.82 | $0.10 | ||
| Q2 25 | $0.93 | $-0.01 | ||
| Q1 25 | $0.83 | $-0.23 | ||
| Q4 24 | $0.57 | $0.40 | ||
| Q3 24 | $0.79 | $-0.02 | ||
| Q2 24 | $0.88 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $354.6M |
| Total Assets | $8.6B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $137.5M | ||
| Q3 25 | $659.9M | $135.4M | ||
| Q2 25 | $785.1M | $116.9M | ||
| Q1 25 | $621.4M | $112.9M | ||
| Q4 24 | $615.9M | $116.2M | ||
| Q3 24 | $573.7M | $101.7M | ||
| Q2 24 | $535.8M | $102.5M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $354.6M | ||
| Q3 25 | $1.1B | $321.9M | ||
| Q2 25 | $1.1B | $306.8M | ||
| Q1 25 | $1.1B | $295.5M | ||
| Q4 24 | $1.0B | $292.0M | ||
| Q3 24 | $1.0B | $257.5M | ||
| Q2 24 | $996.6M | $243.0M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $488.0M | ||
| Q3 25 | $8.5B | $453.3M | ||
| Q2 25 | $8.4B | $435.6M | ||
| Q1 25 | $8.2B | $424.6M | ||
| Q4 24 | $8.1B | $432.7M | ||
| Q3 24 | $8.1B | $390.4M | ||
| Q2 24 | $8.0B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $15.0M | ||
| Q3 25 | $49.4M | $22.1M | ||
| Q2 25 | $15.0M | $8.2M | ||
| Q1 25 | $26.4M | $6.6M | ||
| Q4 24 | $101.1M | $22.2M | ||
| Q3 24 | $48.1M | $10.2M | ||
| Q2 24 | $20.9M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $12.8M | ||
| Q3 25 | $47.6M | $19.5M | ||
| Q2 25 | $13.0M | $81.0K | ||
| Q1 25 | $24.3M | $-7.6M | ||
| Q4 24 | $95.7M | $8.5M | ||
| Q3 24 | $47.1M | $-9.2M | ||
| Q2 24 | $19.9M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | 13.8% | ||
| Q3 25 | 44.4% | 28.8% | ||
| Q2 25 | 12.3% | 0.1% | ||
| Q1 25 | 25.3% | -14.5% | ||
| Q4 24 | 97.0% | 11.2% | ||
| Q3 24 | 47.9% | -15.9% | ||
| Q2 24 | 20.6% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 2.4% | ||
| Q3 25 | 1.6% | 3.9% | ||
| Q2 25 | 1.9% | 12.9% | ||
| Q1 25 | 2.1% | 27.0% | ||
| Q4 24 | 5.5% | 18.3% | ||
| Q3 24 | 1.1% | 33.5% | ||
| Q2 24 | 1.1% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | 0.65× | ||
| Q3 25 | 2.13× | 4.35× | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | 1.12× | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
